Antibiotic Resistance Mechanisms Inform Discovery: Identification and Characterization of a Novel Amycolatopsis Strain Producing Ristocetin by Truman, Andrew W et al.
 1 
 
 1 
 2 
Antibiotic Resistance Mechanisms Inform Discovery: Identification and Characterization of a Novel 3 
Amycolatopsis Strain Producing Ristocetin  4 
 5 
 6 
Andrew W. Truman,a* Min Jung Kwun,b Jinhua Cheng,c Seung Hwan Yang,c Joo-Won Suh,d# 7 
 Hee-Jeon Hongb# 8 
 9 
Department of Chemistry, University of Cambridge, Cambridge, United Kingdoma; Department of 10 
Biochemistry, University of Cambridge, Cambridge, United Kingdomb; Center for Neutraceutical and 11 
Pharmaceutical Materials, Myongji University, Yongin, Republic of Koreac; Division of Bioscience 12 
and Bioinformatics, College of Natural Science, Myongji University, Yongin, Republic of Koread  13 
 14 
Running Title: Antibiotic Resistance Mechanisms Inform Discovery 15 
 16 
#Address correspondence to Joo-Won Suh, jwsuh@mju.ac.kr, or Hee-Jeon Hong, hh309@cam.ac.uk.  17 
*Present address: Andrew W. Truman, Department of Molecular Microbiology, John Innes Centre, 18 
Norwich, United Kingdom. 19 
A.W.T., M.J.K. and J.C. contributed equally to this work. 20 
 21 
 22 
 23 
 24 
 2 
 
 25 
ABSTRACT 26 
 27 
Discovering new antibiotics is a major scientific challenge, made increasingly urgent by the continued 28 
development of resistance in bacterial pathogens. A fundamental understanding of the mechanisms of 29 
bacterial antibiotic resistance will be vital for the future discovery or design of new, more effective 30 
antibiotics. We have exploited our intimate knowledge of the molecular mechanism of glycopeptide 31 
antibiotic resistance in the harmless bacterium Streptomyces coelicolor to develop a new two-step cell 32 
wall bioactivity screen that efficiently identified a new actinomycete strain containing a previously 33 
uncharacterized glycopeptide synthetic gene cluster. The screen first identifies natural product extracts 34 
capable of triggering a generalized cell wall stress response mechanism, then subsequently specifically 35 
selects for glycopeptide antibacterials by assaying for induction of glycopeptide resistance genes. In 36 
this study, we have established a diverse natural product extract library from actinomycetes strains 37 
isolated from locations with widely varying climates and ecologies and screened them using the novel 38 
two-step bioassay system. The bioassay ultimately identified a single strain harboring the previously 39 
unidentified biosynthetic gene cluster for the glycopeptide ristocetin providing a proof-of-principle for 40 
the effectiveness of the screen. This is the first report of the ristocetin biosynthetic gene cluster which is 41 
predicted to include some interesting and previously uncharacterized enzymes. By focusing on 42 
screening libraries of microbial extracts this strategy provides the certainty that identified producer 43 
strains are competent for growth and the biosynthesis of the detected glycopeptide under laboratory 44 
conditions. 45 
 46 
 47 
INTRODUCTION 48 
 3 
 
 49 
Recent years have seen ever increasing numbers of cases of infections caused by drug-resistant 50 
bacteria, creating an urgent need for new and improved antibiotics (1). Unfortunately, traditional 51 
antibiotic research and development has decreased during this period leading to a reduction in the 52 
antibiotic discovery pipeline and a developing public health crisis. Understanding how antibiotics can 53 
fail to be active is vital knowledge for the development of future novel antimicrobials. Such 54 
information is often linked intimately to the drug’s mode of action, and therefore can provide unique 55 
insights that can be used to help discover and design novel compounds, or to develop new ways of 56 
prolonging the therapeutic usefulness of existing ones. Such efforts can be assisted by recent advances 57 
in genetic engineering and synthetic biology approaches that will facilitate the targeted modification of 58 
existing antibiotic structures (2). These techniques however rely on the supply of a diverse range of 59 
well characterized antibiotic scaffold-modifying enzymes to be called upon to specifically expand the 60 
chemical diversity of the natural structures available. The discovery of new enzyme activities can 61 
therefore be seen as an important goal in itself, alongside the larger goal of identifying novel natural 62 
antibiotics. 63 
The bacterial cell wall is an important and validated target for antibacterial chemotherapy; it is 64 
crucial for bacterial cell growth by providing a physical protective barrier between the cell and its 65 
environment, and is an important mediator of the innate immune response during bacterial infections. 66 
Antibiotics that inhibit bacterial cell wall biosynthesis are therefore clinically important in the 67 
treatment of infectious diseases. Understanding bacterial cell wall biosynthesis has been the subject of 68 
intensive study from the time of the discovery of penicillin, the first clinically available antibiotic 69 
targeting peptidoglycan biosynthesis, up to the present day in analyses of the distinct mode of action of 70 
glycopeptide antibiotics such as vancomycin. Vancomycin inhibits the completion of bacterial cell wall 71 
peptidoglycan biosynthesis by non-covalently binding to the teminus of growing peptidoglycan, D-72 
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alanyl-D-alanine (D-Ala-D-Ala) (3). For more than 50 years, vancomycin has been reserved as an 73 
antibiotic of last resort for the treatment of infectious diseases caused by Gram-positive bacteria, 74 
particularly methicillin-resistant Staphylococcus aureus (MRSA). However, in common with the other 75 
antibiotics in mainstream use, resistance to glycopeptides has spread through bacterial populations, 76 
with the first clinical isolates of vancomycin-resistant Enterococci (VRE) being identified in the 77 
1980’s, and vancomycin-resistant MRSA (VRSA) emerging at the beginning of the new millennium 78 
(4). It was soon revealed that these resistant strains have responded to the challenge of vancomycin by 79 
replacement of the D-Ala-D-Ala terminus of peptidoglycan precursors with D-alanyl-D-lactate (D-Ala-80 
D-Lac) resulting in an approximately 1000-fold lower binding affinity for vancomycin and 81 
consequently rendering the modified bacteria resistant to the antibiotic (3). This peptidoglycan 82 
remodelling requires expression of at least three genes, vanHAX. Transcription of vanHAX is usually 83 
regulated by VanS and VanR two-component system regulatory proteins and genes encoding these 84 
proteins are often found adjacent to vanHAX.  85 
Research into the mechanism of glycopeptide antibiotic resistance initially focused on the 86 
pathogenic bacterial strains (5-7), but the complexity of the resistance system uncovered soon led to the 87 
speculation that the resistance genes may have originated from an antibiotic producing organism where 88 
they had co-evolved for self-protection. Streptomyces coelicolor is a model organism for the 89 
actinomycetes, the genus responsible for the production of the two-thirds of clinically important 90 
antibiotics (8). It does not synthesize any glycopeptide antibiotics but does possess a vancomycin 91 
resistance cluster (vanRSJKHAX) (9). S. coelicolor has consequently emerged as a safe and convenient 92 
model system for the in vivo study of glycopeptide resistance, and has provided a detailed 93 
understanding both of the specific mechanisms of resistance and how these are integrated with the 94 
more generalized mechanisms for bacterial cell wall homeostasis (9-17). This knowledge has allowed 95 
us to develop some simple but effective bioassay tools for identifying antimicrobial agents that are 96 
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active against cell wall biosynthesis, and here we report their use to screen a large natural product 97 
extract library for novel glycopeptide antibiotics. 98 
 99 
 100 
MATERIALS AND METHODS 101 
 102 
Bacterial strains, media, oligonucleotides, and growth conditions.  103 
Bacterial strains, plasmids, oligonucleotides and media for this study are described in Tables S1-S3 104 
respectively. Except where described here, media and culture conditions were as given previously (18). 105 
 106 
Construction of the natural product extract library.  107 
To establish the extract library, soil samples were first collected from diverse sites around south-eastern 108 
Asia, focusing on environments with unusual weather conditions and ecologies e.g. alpine, tropical, 109 
polar and desert regions. One gram of each soil sample was suspended in 10 ml of 0.85% NaCl solution 110 
and serially diluted. The serial dilutions were spread on Humic acid-Vitamin (HV) agar medium (19) to 111 
isolate actinomycete strains (see Table S2 in the supplemental material). After incubation at 30 °C for 7 112 
days any single colony displaying a representative actinomycete morphology was isolated by streaking 113 
on  modified Bennett’s (m-BN) agar medium or Gauze’s No. 1 (GN1) agar medium (20) (see Table 114 
S3). This also provided the opportunity to further confirm the actinomycete colony morphology. After 115 
incubation at 30°C for an additional 7 days, the surface of each plate was scraped with sterile cotton 116 
wool soaked in 20% glycerol solution. The cotton wool was then squeezed into an empty sterile tube to 117 
collect the filtered spores or mycelium suspension of the selected actinomycete strain and stored at -80 118 
°C.  119 
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For the preparation of the crude metabolite extracts, 0.5 ml of spore (or aerial mycelium) glycerol 120 
stock solution of each isolate was inoculated in 30 ml each of three different liquid media; Bennett’s 121 
(BN) medium, Glucose Soybean Starch (GSS) medium, and Dextrin Yeast Corn steep liquor (DYC) 122 
medium (Table S3). After incubation at 30 °C and 280 rpm for 6 days in a 250 ml sterile flask 123 
containing a 30 cm coiled stainless steel spring baffle, each culture broth was centrifuged for 5 min at 124 
1,500 g. The supernatant was poured into 30 ml of ethyl acetate and extracted for 5 min by vortexing 125 
vigorously. Following phase separation, the ethyl acetate layer was evaporated to dryness and re-126 
dissolved in 3 ml methanol. The aqueous phase was mildly heated (60 °C) for 30 min to remove ethyl 127 
acetate remained in aqueous phase and freeze-dried, then re-dissolved in 3 ml water. The cell pellet was 128 
extracted with 3 ml of methanol by vigorous vortexing for 20 min then centrifuged for 5 min at 1,500 g 129 
to remove cell debris. 30 μl aliquots of each extract were added to 96 well plates, freeze dried and 130 
stored at 4 °C. Each actinomycete isolate consequently generates nine different extracts. The full 131 
extract library currently consists of approximately 150,000 natural product extracts from over 15,000 132 
different actinomycete strains. The library has been give the acronym ECUM (Extract Collection of 133 
Useful Microorganisms) and is further described at www.ecum.or.kr. 134 
 135 
Screening the extract library and isolation of MJM2582.  136 
Each freeze-dried actinomycete extract aliquot from the 96 well plates was dissolved in 30 μl dimethyl 137 
sulfoxide (DMSO) and 10 µl was used per screening assay. For the first-round screening using the 138 
sigEp-neo fusion reporter system, approximately 107 spores of S. coelicolor M600 carrying pIJ6880 (a 139 
multi-copy, promoter probe plasmid, pIJ486, carrying sigEp-neo fusion DNA; see Table S1 in the 140 
supplemental material) were spread on 12 cm × 12 cm MMCGT agar plates containing 100 μg/ml of 141 
kanamycin. 6 mm sterile paper discs impregnated with the 10 μl DMSO extract sample were applied to 142 
the surface of the freshly spread plates, and activity scored after incubation at 30 °C for 2-4 days.     143 
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Positive inducers of the sigE promoter raise the level of expression of the neo gene and hence 144 
produce a halo of kanamycin-resistant growth around the paper disc. The number of isolates tested for 145 
the first-round screening was over 5,300, with ~260 strains (about 5%) giving a positive response. 146 
These positive extracts were subjected to a second-round of screening using the ∆femX mutant strain to 147 
identify those containing glycopeptide antibiotics capable of inducing van gene expression (explained 148 
in detail in the Results section). Approximately 107 spores of S. coelicolor ∆femX mutant strain J3130 149 
(see Table S1) were spread on MMCGT agar medium containing no antibiotic, and 10 μl DMSO 150 
solutions of the selected inducer extracts were applied on paper discs to the plate. Plates were incubated 151 
at 30 °C for 2-4 days. Positive inducers produced a halo of glycopeptide-dependent growth of S. 152 
coelicolor ∆femX around the disc.  153 
A single strain, designated as Amycolatopsis species MJM2582, was isolated from the 260 tested 154 
from the first round screen. Among the 9 different extracts from MJM2582 tested, very strong and clear 155 
induction halo were all observed from extracts prepared from aqueous and methanol extracts. In 156 
contrast, negligible halos were observed from extracts prepared from the ethyl acetate layer. This is 157 
consistent with the water solubility and organic solvent insolubility of glycopeptide antibiotics. 158 
  159 
Genomic DNA extraction, sequencing and annotation.  160 
The genomic DNAs of MJM2582 and Amycolatopsis lurida were isolated by modification of the 161 
‘Kirby mix procedure’ according to the method described previously (18). Each strain was cultured in 162 
10 ml Tryptic Soy Broth (TSB, Oxoid) liquid medium at 30 °C 280 rpm for 2 days. The harvested 163 
mycelia were washed twice with an equal volume of 10.3% sucrose and then lysed in 1 ml of lysozyme 164 
solution (2 mg/ml lysozyme in 10.3% sucrose, 25 mM Tris (pH8), 25 mM EDTA, pH8) by incubating 165 
at 30 °C for 10 min. The lysate was extracted with 1 ml of 2 × Kirby mix (2 g sodium tri-166 
isoprophylnaphthalene sulphonate, 12 g sodium 4-amino-salicylate, 5 ml 2 M tris-HCl (pH8), 6 ml 167 
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phenol mixture and made up to 100 ml with water) and 2 ml of phenol/chloroform solution 168 
(phenol:chloroform (1:1 v/v), equilibrated with 0.1M Tris, pH8), and 1 ml of phenol/chloroform. The 169 
nucleic acids in upper phase were transferred to a fresh tube and precipitated with 1/10 volume of 3 M 170 
sodium acetate (pH6) and an equal volume of isopropanol at room temperature for 10 min. The pellet 171 
of nucleic acids obtained by centrifugation was then resuspended in RNase solution (50 μg/ml of 172 
RNaseI in 500 μl Tris-EDTA (TE) buffer) and incubated for 30 min at 37 °C to remove all RNAs. The 173 
genomic DNA sample was cleaned by extraction with 200 μl of phenol/chloroform, and isopropanol 174 
precipitation as described above. The DNA pellet obtained after centrifugation was washed with 70% 175 
ethanol and dissolved in TE buffer solution (25 mM Tris (pH7.5), 2 ml EDTA).  176 
Whole genome sequencing was performed by the DNA sequencing facility at the Department of 177 
Biochemistry, University of Cambridge using a combined Illumina MiSeq and Roche 454 sequencing 178 
approach. Assembly using the 454 GS De Novo Assembler (v.2.8) produced a draft sequence of 9.3 179 
Mb in 149 contigs. Anti-SMASH 2.0 (http://www.secondarymetabolites.org/) (21, 22) was used to 180 
identify a single glycopeptide gene cluster in each genome sequence. The DNA sequence of the cluster 181 
from MJM2582 and A. lurida has been deposited in the GenBank database under accession number 182 
KF882511 and KJ364518. Sequence comparison studies with previously reported glycopeptide 183 
biosynthetic clusters i.e. teicoplanin, balhimycin, A47934, chloroeremomycin, dalbavancin and 184 
vancomycin were performed using the ACT web comparison tool (23). Artemis (24) and Glimmer 3.02 185 
(25) were used for prediction and annotation of open reading frames (Orfs) in the cluster sequence. 186 
 187 
Extraction and purification of glycopeptide antibiotics.  188 
Aerial mycelia (or spores) of each glycopeptide producer strain of interest (Amycolatopsis species 189 
MJM2582, Amycolatopsis lurida, Streptomyces toyocaensis, Amycolotopsis balhimycina) (see Table S1 190 
in the supplemental material) were prepared from 7 day cultures on Soya Flour Mannitol (SFM) agar 191 
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medium or BN agar medium at 30 °C (see Table S2). MJM2582 was tested for preparative 192 
glycopeptide production in media previously reported for the production of A47934 (26), teicoplanin 193 
(27), vancomycin (28) and ristocetin (29). Bioassays using S. coelicolor ∆femX and S. coelicolor 194 
∆vanRS strain showed that the only medium that reliably yielded glycopeptides was Streptomyces 195 
Antibiotic Medium (SAM) used for A47934 biosynthesis (26). Seed cultures of MJM2582 were 196 
prepared by transferring its mycelia (or spores) to 25 ml Glucose Yeast extract Malt extract (GYM) 197 
liquid medium (20) in a 250 ml Erlenmeyer flask containing a 30 cm stainless steel spring wire and 198 
incubating at 30 °C for 48 h with shaking at 250 rpm (see Table S3). 2.5 ml of dense seed culture was 199 
then used to inoculate 50 ml SAM medium in 250 ml Erlenmeyer flasks containing spring wire baffles. 200 
After incubation at 30 °C for 6 days with shaking at 250 rpm, the culture broth was centrifuged and the 201 
cell pellet was extracted with 1% NH4OH (1 ml per 1 g wet pellet). This mixture was centrifuged and 202 
the alkaline supernatant harvested and neutralized with HCl. This pellet extract was used for initial 203 
bioassay screening and a similar process was used to obtain glycopeptide extracts from S. toyocaensis 204 
and A. balhimycina.   205 
The MJM2582 glycopeptide was further purified by combining its pellet extract with the culture 206 
supernatant, which was then applied to Diaion HP20 resin. The resin was washed with a step-wise 207 
gradient of water and methanol to elute the bound glycopeptides (50-80% methanol). Fractions 208 
containing glycopeptides were pooled and further purified using a D-Ala-D-Ala affinity resin. This was 209 
prepared and used as previously described (30) and yielded a mixture of glycopeptides. Individual 210 
glycopeptides were obtained by preparative HPLC (Agilent 1200) using a Phenomenex Luna C18(2) 211 
column (250 mm × 21.2 mm, 10 μm), eluting with a linear gradient of 5 to 95% acetonitrile (+ 0.1% 212 
TFA) in water (+ 0.1% TFA) over 35 min with a flow-rate of 20 ml/min. UV detection was performed 213 
at 280 nm.  214 
 215 
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Additional antibiotic bioassays.  216 
All other antibiotic susceptibility, resistance and induction tests using S. coelicolor strains were 217 
performed on Minimal Medium plus Casaminoacids Glucose Tiger milk (MMCGT) agar medium (see 218 
Table S2 in the supplemental material). Approximately 107 spores of S. coelicolor strains were spread 219 
on 12 cm × 12 cm square plates, or for 9 cm diameter round plates 105 spores were used. 10-30 μl of 220 
antibiotic solution (containing 30 μg antibiotic) was then soaked into sterile 6 mm paper discs and 221 
applied to the freshly spread spore lawns and incubated at 30 °C for 2-4 days before scoring. For 222 
antibiotic susceptibility tests using Bacillus subtilis, Enterococcus faecalis and Staphylococcus aureus, 223 
plates were prepared by mixing a 200 μl aliquot from an overnight liquid culture of each strain with 20 224 
ml of just-molten LB soft agar (18) and set at room temperature. Plates were scored after incubation at 225 
37 °C for 18 h. For bioassays using antibiotic solution made from commercially available antibiotic 226 
powder, 30 μg of antibiotic was applied. For bioassays performed using glycopeptide antibiotics 227 
extracted from producer strains, 20 μl of a neutralized NH4OH extract solution was used. All tested 228 
antibiotics were purchased either from Sigma-Aldrich or Oxoid.  229 
 230 
Mass spectrometry analysis of glycopeptide antibiotics.  231 
Glycopeptide antibiotics were analyzed by liquid chromatography - mass spectrometry (LC-MS; 232 
Agilent 1100 HPLC coupled to a Thermo Scientific LCQ with an ESI source in positive-ion mode) 233 
using a Phenomenex Luna C18(2) column (250 mm × 2.0 mm, 5 μm), eluting with a linear gradient of 234 
5 to 95% acetonitrile (+ 0.1% TFA) in water (+ 0.1% TFA) over 25 min with a flow-rate of 0.3 ml/min. 235 
UV detection was performed at 280 nm. The major components after D-Ala-D-Ala resin purification 236 
were m/z = 1773.3, 1759.3, 1034.3 and 1027.3. High-resolution mass spectrometry was recorded on a 237 
Thermo Scientific LTQ Orbitrap and yielded the major component with an isotopic pattern of m/z = 238 
1034.3386, 1034.8396, 1035.3406, 1035.8416, 1036.3429. This is identical to the pattern generated 239 
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from authentic ristocetin A ([M+2H]2+; C95H112N8O442+) of m/z = 1034.3385, 1034.8395, 1035.3404, 240 
1035.8415, 1036.3427.   241 
 242 
 243 
RESULTS 244 
 245 
Extensive screening of microbial extracts library using a novel two-step bioassay system 246 
identified an Amycolatopsis strain producing glycopeptide antibiotic.  247 
For this study, we have initially established a geographically diverse collection of actinomycte strains. 248 
Each actinomycte strain was then cultured in three different liquid media and extracted with three 249 
different solvents consequently generating a total nine different natural product extracts. A randomly 250 
selected subset of this library covering ~5,300 actinomycete isolates was screened using a two-step 251 
procedure involving an initial bioassay using a sigEp-neo fusion reporter strain to identify extracts 252 
capable of triggering a generalized cell wall stress response (10), followed by a growth assay using a 253 
∆femX mutant strain to identify specific glycopeptide antibiotic activity (11, 12) (Fig. 1A). sigE 254 
encodes an extracytoplasmic function (ECF) sigma factor, σE, which is part of a signal transduction 255 
system that senses and responds to cell wall stress and is therefore required for normal cell wall 256 
integrity in S. coelicolor (31). Expression of sigE is induced by a wide-variety of agents that stress the 257 
cell wall, and wild-type S. coelicolor harbouring a multi-copy sigEp-neo fusion reporter plasmid 258 
(pIJ6880; see Table S1 in the supplemental material) in which the aminoglycoside phosphotransferase 259 
gene (neo) is expressed under the control of the sigE promoter only exhibits kanamycin-resistant 260 
growth in the presence of such compounds (Fig. 1B). About 5% of the extracts tested strongly activated 261 
expression of the sigEp-neo fusion, and these were subjected to a second round of screening using a 262 
∆femX mutant bioassay system. FemX adds a single branched glycine to the stem pentapeptide of 263 
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peptidoglycan precursors during cell wall biosynthesis, and is essential for growth under normal 264 
conditions. During exposure to vancomycin however, induction of the vanHAX genes remodels 265 
peptidoglycan biosynthesis to produce precursors with pentapeptide chains terminating with D-Ala-D-266 
Lac instead of D-Ala-D-Ala. This modification confers resistance to vancomycin but FemX cannot 267 
efficiently use D-Ala-D-Lac-containing precursors as substrates, and under these growth conditions this 268 
function is instead performed via induction of the homologous enzyme VanK. FemX therefore 269 
becomes non-essential provided that the van genes are expressed (11). As a consequence, the ∆femX 270 
mutant strain is viable in the presence of vancomycin but non-viable in its absence, making growth of 271 
the ∆femX mutant itself a simple drug-dependent bioassay system for specifically screening for 272 
glycopeptide antibiotics (Fig. 1B). Of the 260 strains with extracts producing a positive response in the 273 
first round screen, extracts from a single isolate were found to strongly induce ∆femX growth in the 274 
glycopeptide bioassay. Susceptibility tests using vancomycin sensitive and resistant (inducible and 275 
constitutive) bacterial strains provided further evidence for the presence of a glycopeptide antibiotic in 276 
the positive extract (Fig. 1C; see also Fig. S1 in the supplemental material). The 16S rRNA gene 277 
sequence of the producing strain was next determined as a filter to guard against the rediscovery of 278 
known glycopeptide producer strains, and indicated a previously unidentified Amycolatopsis species 279 
which we designated Amycolatopsis sp. MJM2582 (Fig. 2; see also Fig. S2).  280 
 281 
Amycolatopsis sp. MJM2582 produces ristocetin.  282 
To fully characterize the glycopeptide produced by MJM2582, a draft genome sequence was produced 283 
to access the genes in the biosynthetic cluster, and culture extracts were analyzed using LC-MS. 284 
Comparative analysis using sequences from a number of previously reported glycopeptide biosynthetic 285 
clusters including teiocoplanin (32), balhimycin (33), A47934 (34), dalbavancin (35) and vancomycin 286 
(36), indicates that MJM2582 carries a novel ~79 kb gene cluster consisting of 39 Orfs (Fig. 3; see also 287 
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Fig. S3 and Table S4 in the supplemental material). LC-MS analysis identified a number of related 288 
glycopeptides produced by MJM2582. A single component eluting at 9.0 min and with m/z = 1034 is 289 
identical to an authentic standard of ristocetin A ([M+2H]2+ = 1034) indicating that the predicted 290 
structure of the glycopeptide from MJM2582 corresponds to ristocetin A (Fig. 4; see also Figs. S4 and 291 
S5 in the supplemental material). The other compounds are consistent with O-desmethyl ristocetin A 292 
([M+2H]2+ = 1027), ristocetin B ([M+H]+ = 1773) and O-desmethyl ristocetin B ([M+H]+ = 1759) (Fig. 293 
5; see also Fig. S6). This is the first report of the biosynthetic gene cluster for ristocetin, and identifies a 294 
second producer strain for this glycopeptide, which had previously been isolated from Amycolatopsis 295 
lurida (37). Genome sequencing of A. lurida showed that it carries a gene cluster with an identical 296 
organization and 91% nucleotide identity. 297 
  298 
Analysis of the ristocetin gene cluster. In comparison to previously characterized glycopeptide 299 
clusters, the ristocetin cluster has a number of interesting and distinctive features (see Fig.S3 and Table 300 
S4 in the supplemental material). It possesses six genes encoding glycosyltransferase (GT) enzymes, 301 
which is more than any previously reported cluster and reflects the complex pattern of glycosylation in 302 
the antibiotic produced. Phylogenetic analysis of the GTs indicates the presence of four class B and two 303 
class C enzymes that handle the attachment of the D-arabinose, D-glucose, L-rhamnose, L-ristosamine 304 
and two D-mannose sugars to the ristocetin aglycone (see Fig. S7 in the supplemental material). 305 
Bacterial class C GTs catalyze mannosylation using undecaprenyl-phospho-mannose as a donor, 306 
whereas class B GTs utilize a wide variety of NDP-activated sugars (38). The sugars required for 307 
ristocetin production can all be accessed from generalized bacterial metabolism with the notable 308 
exception of L-ristosamine, a rare dideoxy sugar that requires dedicated genes in the cluster for its 309 
biosynthesis. We propose a route to TDP-activated L-ristosamine via activity of the enzymes encoded 310 
by Orfs 30-33 in the cluster (Fig. 6). These are homologous to genes in the chloroeremomycin cluster 311 
 14 
 
which produce the related sugar epivancosamine (39), a methylated derivative of L-ristosamine 312 
additionally requiring a 3-C-methyltransferase (MT) that is absent from the ristocetin cluster. Another 313 
unusual feature of ristocetin is its methylation pattern: O-methylation of the carboxyl terminus of the 314 
core peptide and C-methylation of (S)-3,5-dihydroxyphenylglycine (Dpg) at amino acid position 3. 315 
Accordingly, two MTs are encoded in the gene cluster (see Fig. 3). Orf19 shares significant homology 316 
with VEG18 which catalyses the C-terminal O-methylation of a glycopeptide aglycone (40) while 317 
Orf23 does not share homology with any previously characterized glycopeptide MTs and is therefore 318 
the candidate for the C-methylation of the ristocetin aglycone (see Table S4 in the supplemental 319 
material). This modification is unique amongst characterized glycopeptide pathways.  320 
The four non-ribosomal peptide synthetase (NRPS) proteins in the ristocetin gene cluster have a 321 
similar domain organization and predicted adenylation domain specificity to the teicoplanin NRPS and 322 
assemble a peptide from β-hydroxytyrosine (βHTy), (S)-4-hydroxyphenylglycine (Hpg) and Dpg (Fig. 323 
7; see also Table S5 in the supplemental material) (41). The rigid teicoplanin-like ristocetin aglycone is 324 
then predicted to be generated by four cytochrome P450 enzymes encoded by adjacent genes (Orfs12-325 
15), which in previously characterized pathways are known to form oxidative cross-links between the 326 
aromatic amino acid side chains (32). Interestingly, while the organization of the NRPS into four 327 
proteins with a module distribution of 2-1-3-1 is a feature common to teicoplanin-like (Type IV) 328 
glycopeptides, the organization of the tailoring enzymes is much more closely related to vancomycin-329 
like (Type I) glycopeptides. Furthermore, while Dpg and Hpg biosynthesis is conserved between the 330 
production of teicoplanin-like and vancomycin-like glycopeptides, distinct routes have evolved for 331 
βHTy biosynthesis, where a single non-heme dioxygenase is used for the former (42), and three 332 
separate enzymes for the latter (43). Ristocetin employs the same route as vancomycin (Orfs 25-27), 333 
despite a teicoplanin-like aglycone. Ristocetin is the only non-chlorinated glycopeptide antibiotic 334 
reported to date, and the gene cluster unsurprisingly does not encode a halogenase.  335 
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The 5’-end of the ristocetin gene cluster is marked by the presence of the vanHAX glycopeptide 336 
resistance system required for reprograming cell wall peptidoglycan biosynthesis (see Fig. 3). However 337 
no genes encoding the VanRS two-component regulatory system were identified anywhere in both the 338 
MJM2582 and S. lurida genome, implying that vanHAX expression may be constitutive in this strain or 339 
otherwise controlled in a VanRS-independent manner. Interestingly, alignment of the vanHAX 340 
promoter sequence in ristocetin gene cluster with similar sequences from other glycopeptide gene 341 
clusters identified conserved nucleotide changes in those with no obvious VanRS control system in 342 
comparison to those known to be regulated by VanRS (Fig. 8). This implies that the putatively VanRS-343 
independent promoters may share the same method of regulation.  344 
 345 
 346 
DISCUSSION 347 
 348 
We have identified the previously unknown ristocetin gene cluster encoding interesting new enzyme 349 
activities using a two-step screening system developed from an understanding of the detailed molecular 350 
mechanism of glycopeptide resistance in S. coelicolor. Thaker et al. recently reported the discovery of 351 
the novel glycopeptide pekiskomycin using growth in the presence of vancomycin as an initial screen 352 
to enrich for glycopeptide producing strains derived from soil samples (44). A significant proportion 353 
(89/100) of the vancomycin-resistant strains isolated in this way did not however contain glycopeptide 354 
biosynthetic clusters and it was necessary to include an additional PCR based screen to identify those 355 
that do. The ∆femX mutant bioassay employed in this work proved highly specific for compounds 356 
which induce expression of the van resistance genes, and a further discriminatory screen was not 357 
required. Nevertheless, Thaker et al. elegantly exploited the results of their PCR screen to produce 358 
phylogenetic fingerprints for dereplication, discriminating against the rediscovery of known strains and 359 
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compounds, and we believe that the two different screens can be highly complementary. Although 360 
more limited in scope, both also offer significant advantages over the screening of metagenomic 361 
libraries of DNA from soil for natural products biosynthetic clusters where the disconnection between 362 
the producing microbe and the bioactivity of the molecules that are ultimately being sought introduces 363 
a number of formidable technical challenges. Our focused approach has the advantage that any positive 364 
screen hit apriori comes from an actinomycete strain which is both culturable and competent for the 365 
biosynthesis of the detected antibiotic activity under laboratory conditions.  366 
We envisage that the direct relationship between producing organism, genome sequence and 367 
antibiotic activity afforded by our screening procedure will facilitate both the isolation of new 368 
glycopeptide antibiotics, and the provision of novel verified enzyme activities for use in synthetic 369 
biology approaches to explore the production and design of modified antibiotic structures. In addition, 370 
the extracts identified as active in the first round of sigEp-neo screening but inactive in the subsequent 371 
glycopeptide screen, and which were not considered further in this work, provide an enriched library 372 
from which to seek other classes of natural products active against the bacterial cell wall. The native S. 373 
coelicolor VanS sensor is not induced by teicoplanin-like compounds, and we are currently developing 374 
hybrid sensors to broaden the range of glycopeptide structures that can be detected. Only the extracts 375 
that produced a positive response in the sigEp-neo screen would need to be reanalyzed in the improved 376 
hybrid screens. 377 
 378 
 379 
ACKNOWLEDGEMENTS 380 
 381 
This work was supported by funding from the Royal Society, UK (516002.K5877/ROG), the Medical 382 
Research council, UK (G0700141) and St. John’s College, University of Cambridge. We thank Andy 383 
 17 
 
Hesketh (University of Cambridge, Systems Biology Centre) for helpful discussion and comments on 384 
the manuscript.  385 
 386 
 387 
REFERENCES  388 
 389 
1. Levy S, Marshall B. 2004. Antibacterial resistance worldwide: causes, challenges and 390 
responses. Nat. Med. 10:S122-129. 391 
2. Wohlleben W, Mast Y, Muth G, Röttgen M, Stegmann E, Weber T. 2012. Synthetic 392 
biology of secondary metabolite biosynthesis in actinomycetes: Engineering precursor supply as a way 393 
to optimize antibiotic production. FEBS Lett. 586:2171-2176.  394 
3. Leclercq R, Derlot E, Duval J, Courvalin P. 1988. Plasmid-mediated resistance to 395 
vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. 319:157-161.  396 
4. Pearson H. 2002 ‘Superbug’ hurdles key drug barrier. Nature 418:469-470. 397 
5. Billot-Klein D, Gutmann L, Bryant D, Bell D, Van Heijenoort J, Grewal J, Shlaes DM. 398 
1996. Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing 399 
levels of resistance to glycopeptide antibiotics. J. Bacteriol. 178:4696-4703. 400 
6. Arthur M, Reynolds P, Courvalin P. 1996. Glycopeptide resistance in enterococci. Trends 401 
Microbiol. 4:401-407.  402 
7. Courvalin P. 2005. Genetics of glycopeptide resistance in gram-positive pathogens. Int. J. 403 
Med. Microbiol. 294:479-486.  404 
8. Bentley SD, Chater KF, Cerdeño-Tárraga AM, Challis GL, Thomson NR, James KD, 405 
Harris DE, Quail MA, Kieser H, Harper D, Bateman A, Brown S, Chandra G, Chen CW, Collins 406 
M, Cronin A, Fraser A, Goble A, Hidalgo J, Hornsby T, Howarth S, Huang CH, Kieser T, Larke 407 
 18 
 
L, Murphy L, Oliver K, O'Neil S, Rabbinowitsch E, Rajandream MA, Rutherford K, Rutter S, 408 
Seeger K, Saunders D, Sharp S, Squares R, Squares S, Taylor K, Warren T, Wietzorrek A, 409 
Woodward J, Barrell BG, Parkhill J, Hopwood DA. 2002 Complete genome sequence of the model 410 
actinomycete Streptomyces coelicolor A3(2). Nature 417:141-147. 411 
9. Hong H-J, Hutchings MI, Neu JM, Wright GD, Paget MS, Buttner MJ. 2004. 412 
Characterisation of an inducible vancomycin resistance system in Streptomyces coelicolor reveals a 413 
novel gene (vanK) required for drug resistance. Mol. Microbiol. 52:1107-1121.  414 
10. Hong H-J, Paget MSB, Buttner MJ. 2002. A signal transduction system in Streptomyces 415 
coelicolor that activates the expression of a putative cell wall glycan operon in response to vancomycin 416 
and other cell wall-specific antibiotics. Mol. Microbiol. 44:1199-1211. 417 
11. Hong H-J, Hutchings MI, Hill L, Buttner MJ. 2005. The role of the novel Fem protein VanK 418 
in vancomycin resistance in Streptomyces coelicolor. J. Biol. Chem. 280:13055-13061. 419 
12. Hutchings MI, Hong H-J, Buttner MJ. 2006. The vancomycin resistance VanRS signal 420 
transduction system of Streptomyces coelicolor. Mol. Microbiol. 59:923-935. 421 
13. Hutchings MI, Hong H-J, Leibovitz E, Sutcliffe IC, Buttner MJ. 2006. The σE cell envelope 422 
stress signal of Streptomyces coelicolor is influenced by a novel lipoprotein, CseA. J. Bacteriol. 423 
188:7222-7229. 424 
14. Koteva K, Hong H-J, Wang XD, Nazi I, Hughes D, Naldrett MJ, Buttner MJ, Wright GD. 425 
2010. A vancomycin photoprobe identifies the histidine kinase VanSsc as a vancomycin receptor. Nat. 426 
Chem. Biol. 6:327-329. 427 
15. Hesketh A, Hill C, Mokhtar J, Novotna G, Tran N, Bibb M, Hong H-J. 2011. Genome-wide 428 
dynamics of a bacterial response to antibiotics that target the cell envelope. BMC genomics 12:226. 429 
doi: 10.1186/1471-2164-12-226. 430 
 19 
 
16. Novotna G, Hill C, Vicent K, Liu C, Hong H-J. 2012. A novel membrane protein, VanJ, 431 
conferring resistance to teicoplanin. Antimicrob. Agents Chemother. 56:1784-1796. 432 
17. Kwun MJ, Novotna G, Hesketh AR, Hill L, Hong H-J. 2013. In vivo studies suggest that 433 
induction of VanS-dependent vancomycin resistance requires binding of the drug to D-Ala-D-Ala 434 
termini in the peptidoglycan cell wall. Antimicrob. Agents Chemother. 57:4470-4480. 435 
18. Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA. 2000. Practical Streptomyces 436 
Genetics, The John Innes Foundation, Norwich, UK. 437 
19. Masayuki H, Hideo N. 1987. Humic acid-vitamin agar, a new medium for the selective 438 
isolation of soil actinomycetes. J. Ferment. Technol. 65:501-509.  439 
20. Atlas RM. 2004. Handbook of microbiological media, CRC press. 440 
21. Medema MH, Blin K, Cimermancic P, de Jager V, Zakrzewski P, Fischbach MA, Weber 441 
T, Takano E, Breitling R. 2011. antiSMASH: rapid identification, annotation and analysis of 442 
secondary metabolite biosynthesis gene clusters in bacterial and fungal genome sequences. Nucleic 443 
Acids Res. 39:W339-W346. doi: 10.1093/nar/gkr466. Epub 2011 Jun 14. 444 
22. Blin K, Medema MH, Kazempour D, Fischbach MA, Breitling R, Takano E, Weber T. 445 
2013. antiSMASH 2.0--a versatile platform for genome mining of secondary metabolite producers. 446 
Nucleic Acids Res. 41:W204-W212. doi: 10.1093/nar/gkt449. Epub 2013 Jun 3. 447 
23. Carver T, Berriman M, Tivey A, Patel C, Böhme U, Barrell BG, Parkhill J, Rajandream 448 
MA. 2008. Artemis and ACT: viewing, annotating and comparing sequences stored in a relational 449 
database. Bioinformatics 24:2672-2676. 450 
24. Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, Rajandream MA, Barrell B. 2000. 451 
Artemis: sequence visualization and annotation. Bioinformatics 16:944-945. 452 
25. Delcher AL, Bratke KA, Powers EC, Salzberg SL. 2007. Identifying bacterial genes and 453 
endosymbiont DNA with Glimmer. Bioinformatics 23:673-679.  454 
 20 
 
26. Neu JM, Wright GD. 2001. Inhibition of sporulation, glycopeptide antibiotic production and 455 
resistance in Streptomyces toyocaensis NRRL 15009 by protein kinase inhibitors. FEMS Microbiol. 456 
Lett. 199:15-20. 457 
27. Lee JC, Park HR, Park DJ, Son KH, Yoon KH, Kim YB, Kim CJ. 2003. Production of 458 
teicoplanin by a mutant of Actinoplanes teicomyceticus. Biotechnol. Lett. 25:537-540. 459 
28. Mclntyre JJ, Bull AT, Bunch AW. 1996. Vancomycin production in batch and continuous 460 
culture. Biotechnol. Bioeng. 49:412-420. 461 
29. Philip JE, Forest L, Schenck JR. 1961. Preparation of ristocetin A salts, US patent 2990329 462 
A. 463 
30. Holding AN, Spencer JB. 2008. Investigation into the mechanism of phenolic Ccuplings 464 
during the biosynthesis of glycopeptide antibiotics. ChemBioChem 9:2209-2214. 465 
31. Paget MSB, Emmanuelle L, Buttner MJ. 1999. A putative two-component signal 466 
transduction system regulates σE, a sigma factor required for normal cell wall integrity in Streptomcyes 467 
coelicolor A3(2). Mol. Microbiol. 33:97-107. 468 
32. Li TL, Huang F, Haydock SF, Mironenko T, Leadlay PF, Spencer JB. 2004. Biosynthetic 469 
gene cluster of the glycopeptide antibiotic teicoplanin: characterization of two glycosyltransferases and 470 
the key acyltransferase. Chem. Biol. 11:107-119. 471 
33. Shawky RM, Puk O, Wietzorrek A, Pelzer S, Takano E, Wohlleben W, Stegmann E. 2007. 472 
The border sequence of the balhimycin biosynthesis gene cluster from Amycolatopsis balhimycina 473 
contains bbr, encoding a StrR-like pathway-specific regulator. J. Mol. Microbiol. Biotechnol. 13:76-88. 474 
34. Pootoolal J, Thomas MG, Marshall CG, Neu JM, Hubbard BK, Walsh CT, Wright GD. 475 
2002. Assembling the glycopeptide antibiotic scaffold: The biosynthesis of A47934 from Streptomyces 476 
toyocaensis NRRL15009. Proc. Natl. Acad. Sci. U.S.A. 99:8962-8967.   477 
 21 
 
35. Sosio M, Stinchi S, Beltrametti F, Lazzarini A, Donadio S. 2003. The gene cluster for the 478 
biosynthesis of the glycopeptide antibiotic A40926 by nonomuraea species. Chem. Biol. 10:541-549. 479 
36. Jeong H, Sim YM, Kim HJ, Lee DW, Lim SK, Lee SJ. 2013. Genome sequence of the 480 
vancomycin-producing Amycolatopsis orientalis subsp. orientalis strain KCTC 9412T. Genome 481 
Announc. 1:e00408-00413. doi: 10.1128/genomeA.00408-13. 482 
37. Grundy WE, Sinclair AC, Theriault RJ, Goldstein AW, Rickher CJ, Warren Jr HB, 483 
Oliver TJ, Sylvester JC. 1956-1957. Ristocetin, microbiologic properties. Antibiot. Annu. 687-692. 484 
38. Coutinho PM, Deleury E, Davies GJ, Henrissat B. 2003. An evolving hierarchical family 485 
classification for glycosyltransferases. J. Mol. Biol. 328:307-317. 486 
39. Chen H, Thomas MG, Hubbard BK, Losey HC, Walsh CT, Burkart MD. 2000. 487 
Deoxysugars in glycopeptide antibiotics: enzymatic synthesis of TDP-L-epivancosamine in 488 
chloroeremomycin biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 97:11942-11947. 489 
40. Banik JJ, Brady SF. 2008. Cloning and characterization of new glycopeptide gene clusters 490 
found in an environmental DNA megalibrary. Proc. Natl. Acad. Sci. U.S.A. 105:17273-17277.  491 
41. Donadio S, Sosio M, Stegmann E, Weber T, Wohlleben W. 2005. Comparative analysis and 492 
insights into the evolution of gene clusters for glycopeptide antibiotic biosynthesis. Mol. Genet. 493 
Genomics 274:40-50.  494 
42. Stinchi S, Carrano L, Lazzarini A, Feroggio M, Grigoletto A, Sosio M, Donadio S. 2006. A 495 
derivative of the glycopeptide A40926 produced by inactivation of the β-hydroxylase gene in 496 
Nonomuraea sp. ATCC39727. FEMS Microbiol. Lett. 256:229-235.. 497 
43. Mulyani S, Egel E, Kittel C, Turkanovic S, Wohlleben W, Süssmuth RD, van Pée KH. 498 
2010. The thioesterase Bhp is involved in the formation of beta-hydroxytyrosine during balhimycin 499 
biosynthesis in Amycolatopsis balhimycina. ChemBioChem 11:266-271. 500 
 22 
 
44. Thaker MN, Wang W, Spanogiannopoulos P, Waglechner N, King AM, Medina R, 501 
Wright GD. 2013. Identifying producers of antibacterial compounds by screening for antibiotic 502 
resistance. Nat. Biotechnol. 31:922-927. 503 
 504 
 505 
FIGURE LEGENDS 506 
 507 
FIG 1 Screening for novel glycopeptide antibiotics. (A) Schematic diagram illustrating the application 508 
of a two-step cell wall bioactivity screen to a natural product extract library. Each isolated 509 
actinomycete strain was cultured in three different liquid media and extracted with three different 510 
solvents creating a total nine extracts per strain. Extracts from approximately 5,300 different isolates 511 
were tested in the first round sigEp-neo fusion reporter system, and 260 different isolates gave extracts 512 
which acted as strong inducers. Extracts from these 260 isolates were then subjected to a second round 513 
of screening using ∆femX to identify glycopeptide antibiotics, yielding a single positive isolate 514 
designated MJM2582. (B) Plates demonstrating the response of the sigEp-neo, ∆femX reporter systems 515 
to antibiotics (numbered list shown). Antibiotics that target DNA gyrase (novobiocin), the ribosome 516 
(thiostrepton) or early peptidoglycan biosynthesis (tunicamycin) do not induce the sigEp-neo system, 517 
while those targeting late peptidoglycan biosynthesis (bacitracin, moenomycin A, ramoplanin, 518 
vancomycin, teicoplanin, ristocetin) do. The amount of novobiocin, thiostrepton and tunicamycin used 519 
in the bioassays (30 µg each) is sufficient to produce a halo of growth inhibition when assayed against 520 
S. coelicolor. Extracts obtained from known glycopeptide producer strains (A. balhimycina, S. 521 
toyocaensis) and from MJM2582 also induced the sigEp-neo system. Only glycopeptide antibiotics 522 
(but not teicoplanin) or extracts containing glycopeptides, including MJM2582, acted as inducers in the 523 
ΔfemX bioassay. (C) Bioassay showing the spectrum of activity of the MJM2582 extract against 524 
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glycopeptide sensitive (∆vanRS), constitutively resistant (∆vanS) and inducibly resistant (M600) strains 525 
of S. ceolicolor. 526 
 527 
FIG 2 Phylogenetic analysis of MJM2582 16S RNA sequences. The result indicates that MJM2582 is 528 
a previously unidentified Amycolatopsis species. Scale bar indicates the distance in substitutions per 529 
nucleotide. See also Fig.S2 in the supplemental material. 530 
 531 
FIG 3 Genetic organization of the glycopeptide gene cluster identified in Amycolatopsis sp. MJM2582. 532 
Predicted Orfs are represented by arrows, and numbered consecutively. The predicted enzymatic 533 
function encoded by each Orf is listed. A detailed comparison to the previously reported glycopeptide 534 
clusters can be found in Fig. S3 and Table S4 in the supplemental material. 535 
 536 
FIG 4 LC-MS analysis of the purified glycopeptide extracted from (A) MJM2582 in comparison with 537 
(B) authentic ristocetin A. (C) The predicted structure of the glycopeptide from MJM2582 corresponds 538 
to ristocetin A.  539 
 540 
FIG 5 LC-MS analysis of the array of glycopeptides produced by MJM2582 following partial 541 
purification using HP20 resin. (A) UV chromatogram for the extract and selective ion monitoring 542 
spectra for glycopeptides. (B) Mass spectra for each ristocetin derivative. The spectrometer was tuned 543 
to the [M+2H]2+ ion of teicoplanin to facilitate the identification of compounds above 2000 Da. (C) 544 
Structures and exact masses of ristocetin A and B, and their corresponding desmethyl derivatives. 545 
 546 
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FIG 6 The predicted formation of TDP-ristosamine. The route to TDP-ristosamine was proposed based 547 
on homology of proteins encoded by Orfs 30-33 in the ristocetin gene cluster to the proteins previously 548 
characterized in the TDP-epivancosamine pathway (39).  549 
 550 
FIG 7 Schematic showing the organization of the four NRPSs from the ristocetin gene cluster. The "X" 551 
domain is a non-functional condensation-like domain that is present in all glycopeptide NRPSs (41). 552 
 553 
FIG 8 Alignment of van promoter sequences present in the glycopeptide antibiotic clusters from 554 
Streptomyces coelicolor (Sc), Streptomyces toyocaensis (St), Actinoplanes teichomyceticus (At), 555 
Amycolatopsis balhimycina (Ab), Amycolatopsis orientalis (Ao), Amycolatopsis lurida (Al) and 556 
Amycolatopsis sp. MJM2582 (MJM). The highly conserved sequences represent a putative VanR 557 
response regulator binding site in the -35 and -10 promoter region (boxed). The top four strains (Sc, St, 558 
At, Ab) carry glycopeptide resistance clusters which include genes encoding a VanRS two-component 559 
system, while the bottom three strains (Ao, Al and MJM) lack an obvious VanRS system. Nucleotide 560 
sequence differences identified between these two groups are highlighted.  561 
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-10-35
Sc vanJp ------TCGCCACATATCGTCGGCATATCGAAAACCGCATACGTGCCGGCAACACGCTGCCGCGTTCACTGGGCGT-ATGCGT
vanKp ------CCGGAACATATCGTCGGCGTATCGAAAACCGCATACGCGTCGGCAACGTCCCGCCGCCTTGACTGGGCGC-ATGGCC
vanHp ------AGGTAATATATCGTCAGGATATCGAAAAGCGCATACGGGACGGCAACACCGAGGCGCCTTGAATAGAGGC-ATGACC
St  vanHp ------GCGGGGCGTATCGCGGGCATATCGAAAAGCACATACGTTCCGGCAACAGCACTTCCCCTTGACTGGAGGT-ATGACC
At  vanHp GGGCCCCTCCGACGTATCGTCGGCATATCCAAAACCGCATACGTGCTCGCAACACCACCTTCCCTTGACTGGGCGC-ATGGGT
Ab  vanYp -----------ACATATCGTCGGCATATGGAAAATCGCATACGTGCCGGCAACACATCGCCGACTTGAATGGACAC-ATGACC
Ao vanHp ------TGGTAACTTATTGTCGGGGCATCGAAAACCCCATAAGAAGCGGCAACAACGCGCTGCCTACAATGTCGGGCATGACC
Al  vanHp ------TGGTAACTTATTGTCGAGGCCTCGAAAACCCCATAAGAAGCGGCAACATCGCGCTGCCTACAATGTCGGGCATGACC
MJM vanHp ------TGGTAACTTATTGTCGGGGCATCGAAAACCCCATAAGAAGCGGCAACAACGCGCTGCCTACAATGTCGGGCATGACC
FIG 8 Alignment of van promoter sequences present in the glycopeptide antibiotic clusters from Streptomyces coelicolor
(Sc) Streptomyces toyocaensis (St) Actinoplanes teichomyceticus (At) Amycolatopsis balhimycina (Ab) Amycolatopsis, , , ,
orientalis (Ao), Amycolatopsis lurida (Al) and Amycolatopsis sp. MJM2582 (MJM). The highly conserved sequences
represent a putative VanR response regulator binding site in the -35 and -10 promoter region (boxed). The top four strains
(Sc, St, At, Ab) carry glycopeptide resistance clusters which include genes encoding a VanRS two-component system,
while the bottom three strains (Ao, Al and MJM) lack an obvious VanRS system. Nucleotide sequence differences
identified between these two groups are highlighted.
